| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/21/2002 | WO2002014529A1 Curvularol and process for preparation of the same |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014504A1 Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| 02/21/2002 | WO2002014503A2 Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
| 02/21/2002 | WO2002014500A2 Human genes and gene expression products |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014489A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | WO2002014488A1 Novel protein derived from agkistrodon saxatilis emelianov and process for preparing the same |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014470A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | WO2002014370A1 Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014368A2 Proteins and nucleic acids encoding the same |
| 02/21/2002 | WO2002014365A1 A new polypeptide-ras gtp activator protein 12 and the polynucleotide encoding it |
| 02/21/2002 | WO2002014356A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | WO2002014355A2 Novel mitogen activated kinase |
| 02/21/2002 | WO2002014352A2 Therapeutic compounds for ovarian cancer |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | WO2002014347A2 Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts |
| 02/21/2002 | WO2002014329A1 Compositions with vascular damaging activity |
| 02/21/2002 | WO2002014323A2 Polymorphs of an epothilone analog |
| 02/21/2002 | WO2002014319A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/21/2002 | WO2002014311A2 Urea compounds and methods of uses |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014291A1 PPARδ ACTIVATORS |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014274A1 Selective urokinase inhibitors |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014271A1 Proline derivatives and use thereof as drugs |
| 02/21/2002 | WO2002014267A1 Novel aminocyclohexane derivatives |
| 02/21/2002 | WO2002013882A1 Implants with a phosphazene-containing coating |
| 02/21/2002 | WO2002013864A1 Medicinal compositions for preventing and treating cancer |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013847A2 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 02/21/2002 | WO2002013833A2 SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013817A1 Remedies for cisplatin-tolerant cancer |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013808A2 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | WO2002013804A2 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid |
| 02/21/2002 | WO2002013803A2 Chelerythrine-based therapies for cancer |
| 02/21/2002 | WO2002013802A2 Method of treating estrogen receptor positive carcinoma |
| 02/21/2002 | WO2002013782A1 Oral delivery of peptide |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001079187A3 Substituted 1,4-thiazepine and analogs and their use as activators of caspases |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068802A3 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001064246A3 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 02/21/2002 | WO2001058910A3 Lipid-based drug delivery systems |
| 02/21/2002 | WO2001058904A9 Apoptosis-inducing compounds |
| 02/21/2002 | WO2001057069A3 Targeting peptides |
| 02/21/2002 | WO2001055391A3 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001052789A3 PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001046110A3 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001039803A3 Interleukin-1 muteins useful as vaccine adjuvants |
| 02/21/2002 | WO2001032631A3 Heterocyclic cytotoxic agents |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001019791A3 3-vinylpyrrole derivatives, method for the production thereof and their use as medicaments |
| 02/21/2002 | WO2000078355A3 Biologically active materials |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022781 Products and methods for brachytherapy |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022665 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 02/21/2002 | US20020022658 Methods for selectively occluding blood supplies to neoplasias |
| 02/21/2002 | US20020022655 Leukemic cell growth inhibiting method |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022653 Cannabinoid drugs |
| 02/21/2002 | US20020022652 Methylnogarol compositions and uses thereof |
| 02/21/2002 | US20020022646 Method for systhesizing leflunomide |
| 02/21/2002 | US20020022642 As nitric oxide synthase (NOS) inhibitors, used in therapy and prophylaxis of central nervous system disorders, inflammatory disorders, septic shock and other disorders |
| 02/21/2002 | US20020022640 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 02/21/2002 | US20020022636 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022627 Inhibition of cyclooxygenase-2activity |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022599 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/21/2002 | US20020022597 1-((3,4,5-trihydroxy-6-sulfomethyl-tetrahydropyran-2-yl)-),2 -(fatty acyl),3-(optionally fatty acyl)glycerol; DNA polymerase inhibitors; anticancer agents |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | US20020022036 Administering high molecular weight urine isolate; anticancer, Aids therapy |
| 02/21/2002 | US20020022031 Immunotherapy for chronic myelocytic leukemia |
| 02/21/2002 | US20020022029 Human RRP sequences and methods of use |
| 02/21/2002 | US20020022028 Integrin antagonist; bone disorders |
| 02/21/2002 | US20020022027 Complexing to polypeptides; antiproliferation agent |
| 02/21/2002 | US20020022020 Induction lymphocyte tolerance |